文献速递胸部妇产影像CT

妊娠期CT肺动脉造影有效剂量估算的专用转换系数

CT pulmonary angiography in pregnancy: Specific conversion factors to estimate effective radiation dose from dose length product: A retrospective cross-sectional study across a multi-hospital integrated healthcare network.
PubMed 文献 · Eur J Radiol · 2021-08-13

该回顾性横断面研究纳入534例妊娠期CTPA检查,通过蒙特卡洛模拟确定患者特异性有效剂量并计算k-factor,发现妊娠期专用k-factor均值为0.0249 mSv·mGy⁻¹·cm⁻¹,比通用成人胸部CT的0.014高78%,且受管电压、螺距、患者体型和扫描长度影响,建议使用专用系数估算妊娠期CTPA有效剂量。

要点

  • 妊娠期CTPA的k-factor均值0.0249,显著高于通用胸部CT的0.014,估算有效剂量时不应套用通用系数。
  • 管电压120/140 kVp的k-factor高于80/100 kVp;螺距增大、患者体型增大、扫描长度增加时k-factor降低。
  • 报告妊娠期CTPA剂量时,建议采用妊娠专用k-factor以更准确反映辐射相关癌症风险。

核心结论

  • 妊娠期CTPA的专用k-factor为0.0249 mSv·mGy⁻¹·cm⁻¹,比通用成人胸部CT的0.014高78%(p < 0.001),应使用该专用系数估算妊娠期CTPA有效剂量。

研究设计与样本

  • 回顾性横断面研究,纳入2012年1月至2017年4月多医院整合医疗网络内534例妊娠期CTPA检查。
  • 通过电子健康记录和辐射剂量指数监测系统获取患者及CTPA相关数据。
  • 采用Cristy体模进行患者特异性蒙特卡洛模拟确定有效剂量,除以剂量长度乘积(DLP)得到k-factor。
  • 将妊娠患者k-factor与标准体型成人k-factor进行单样本t检验比较,并对患者和CT预测因素进行双变量和多变量分析。

诊断标准与关键数值

  • 妊娠期CTPA的k-factor均值为0.0249 mSv·mGy⁻¹·cm⁻¹,通用成人胸部CT k-factor为0.014(p < 0.001)。
  • 多变量分析显示k-factor随螺距增大(p = 0.0002)、患者体型增大(p < 0.001)和扫描长度增加(p < 0.0001)而降低。
  • 120 kVp(p < 0.001)和140 kVp(p = 0.0028)分析的k-factor大于80和100 kVp研究合并值。

临床应用与阅片要点

  • 在妊娠期CTPA剂量报告中,应使用专用k-factor 0.0249而非通用胸部CT的0.014来估算有效剂量。
  • 记录管电压、螺距、患者体型和扫描长度,这些因素影响k-factor,有助于个体化剂量评估。
  • 避免将通用成人胸部CT的k-factor直接用于妊娠患者,以免低估辐射相关癌症风险。

局限性

  • 研究为回顾性横断面设计,可能存在选择偏倚。
  • 数据来自多医院网络但未报告外部验证,结论外推需谨慎。
  • 未报告患者特异性因素(如孕周)对k-factor的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: Effective dose describes radiation-related cancer risk from CT scans and is estimated using a readily available conversion factor (k-factor), which varies by body part and study type. To purpose of this study is to determine the specific k-factor for CTPA in pregnant patients and its predictive factors.

METHODS: This retrospective cross-sectional study evaluates CTPA in pregnancy across a multihospital integrated healthcare network from January 2012 to April 2017. Patient and CTPA-related data were obtained from the electronic health record and a radiation dose index monitoring system. Each patient's effective dose was determined by patient-specific Monte-Carlo simulation with Cristy phantoms and divided by patient dose-length-product to determine the k-factor. K-factor for pregnant patients was compared to the k-factor for adults of standard physique with a one-sample t-test. Bivariate and multivariable analyses were performed for patient and CT predictors of k-factor.

RESULTS: A total of 534 patients were included. The mean k-factor for all patients was 0.0249 (mSv·mGy-1·cm-1), 78% greater than k-factor of 0.014 (p < 0.001) suggested for the general adult population. Multivariable analysis demonstrated lower k-factors with increasing pitch (p = 0.0002), patient size (p < 0.001), and scan length (p < 0.0001). The 120 kVp (p < 0.001) and 140 kVp (p = 0.0028) analyses showed a larger k-factor than 80 and 100 kVp studies combined.

CONCLUSIONS: Specific k-factor for CTPA in pregnant patients is greater than the previously used generic chest CT k-factor and should be used to estimate the effective dose for CTPA exams in pregnancy.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Cohen SL, Wang JJ, Chan N, et al. CT pulmonary angiography in pregnancy: Specific conversion factors to estimate effective radiation dose from dose length product: A retrospective cross-sectional study across a multi-hospital integrated healthcare network. Eur J Radiol. 2021. PMID: 34481118. doi:10.1016/j.ejrad.2021.109908

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。